-
Royal Biologics launches new bone graft substitute
Royal Biologics launched its Bio-Reign 3D bone graft substitute, the company said May 23. -
Study supports efficacy of StemSpine procedure
Creative Medical Technology Holdings' StemSpine procedure was found to be effective in treating chronic lower back pain, according to a pilot study. -
Bioventus sells wound care segment
Bioventus sold its wound care segment to LifeNet Health, according to a May 10 news release. -
1,000 patients treated with OssDesign spinal bone graft
OssDesign's Catalyst nanosynthetic bone graft has been used in 1,000 patients, the medtech company said May 9. -
Bioventus CEO steps down
Bioventus' CEO Ken Reali left his post on April 4. -
University of Colorado Medicine opens regenerative orthopedic center
Aurora-based University of Colorado Medicine opened the CU Medicine Regenerative Medicine, Hand and Spine Center in Englewood. -
5 orthobiologics updates in Q1
Here are five updates in orthobiologics and regenerative medicine to know from the first quarter of 2023: -
Minimally invasive cellular allograft system cleared for use in trauma procedures
The world's first viable bone matrix that provides lineage-committed bone cells, LifeNet Health's ViviGen MIS, is now available for use in trauma procedures. -
5 recent developments in orthobiologics
Here are five updates in regenerative medicine since the end of December: -
Royal Biologics launches new platelet-rich plasma system for orthopedics
Orthobiologics company Royal Biologics has commercially launched a new platelet-rich plasma system, Bioincyte. -
3-year data shows efficacy of bone marrow aspirate for spine treatment
A three-year study of Creative Medical Technology Holdings' StemSpine procedure found it was effective for addressing chronic lower back pain. -
2-year data on cell therapy for degenerative disc disease is out: 5 things to know
Orthobiologics company DiscGenics shared data supporting its IDCT (rebonuputemcel) allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease. -
Apex Biologix appoints new CEO
Apex Biologix has chosen Jim Rogers to be the company's next CEO. -
ChitogenX's fiscal year Q3 report: 5 notes
ChitogenX, formerly OrthoRTI, shared its third quarter results for fiscal year 2023. -
5 leading headlines in regenerative medicine
Here are five top-read Becker's headlines on orthobiologics and regenerative medicine in 2022: -
Data supports Orthofix's cellular bone allograft in lumbar fusions
A study published in Neurology International found fusion rates of 98.6 percent with Orthofix's Trinity Elite cellular bone allograft, the devicemaker said Dec. 22. -
California orthopedic center adds PRP knee treatment
NorthBay Health Orthopedics in Vacaville, Calif. added platelet-rich plasma injections for knee injuries, according to a Dec. 18 announcement in the Daily Republic. -
5 developments in orthobiologics
Here are five updates in the orthobiologics industry since Oct. 17: -
Hawaii hospital 1st in state to use BEAR implant
Shriners Children's Hawaii in Honolulu is the first hospital in the state to use the Bridge-Enhanced ACL Restoration, or BEAR, implant, ABC affiliate KITV reported Nov. 23. -
Company's new implantable bone device can save up to $28k per patient
Swedish-based bone graft substitute manufacturer Bonesupport, which received FDA approval for its bone infection indicator Cerament G in May, has found that the new product saves an average of $28,000 per patient according to a Nov. 21 email sent to Becker's.
Page 1 of 50